Exelixis, Inc. $EXEL Shares Sold by Hsbc Holdings PLC

Key Points

• HSBC Holdings reduced its Exelixis stake by 27.9% in the second quarter, selling 18,440 shares and retaining 47,538 shares valued at approximately $2.6 million.
• Exelixis reported quarterly EPS of $0.91, beating estimates of $0.85, while revenue rose 10.6% year over year to $628.7 million. Shares opened at $56.12, near their 52-week high of $59.72.
• The FDA extended its review of Exelixis’ zanzalintinib application for metastatic colorectal cancer by three months, moving the decision target to March 2027 and delaying potential commercial launch visibility.

Hsbc Holdings PLC cut its stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 27.9% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 47,538 shares of the biotechnology company's stock after selling 18,440 shares during the period. Hsbc Holdings PLC's holdings in Exelixis were worth $2,594,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of EXEL. BlackRock Inc. acquired a new stake in Exelixis in the second quarter valued at approximately $1,581,991,000. AQR Capital Management LLC grew its holdings in Exelixis by 48.8% during the 4th quarter. AQR Capital Management LLC now owns 13,658,388 shares of the biotechnology company's stock worth $598,647,000 after acquiring an additional 4,477,029 shares in the last quarter. Invesco Ltd. increased its position in shares of Exelixis by 1.6% in the 4th quarter. Invesco Ltd. now owns 6,054,743 shares of the biotechnology company's stock valued at $265,379,000 after purchasing an additional 94,218 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of Exelixis by 0.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 4,299,597 shares of the biotechnology company's stock valued at $184,391,000 after purchasing an additional 39,920 shares during the last quarter. Finally, Morgan Stanley raised its holdings in shares of Exelixis by 31.0% in the 4th quarter. Morgan Stanley now owns 4,206,656 shares of the biotechnology company's stock valued at $184,378,000 after purchasing an additional 995,949 shares in the last quarter. 85.27% of the stock is owned by institutional investors and hedge funds.

Exelixis Price Performance

Shares of NASDAQ EXEL opened at $56.12 on Friday. The stock has a fifty day moving average price of $55.35 and a 200 day moving average price of $49.98. Exelixis, Inc. has a 1-year low of $33.76 and a 1-year high of $59.72. The company has a market cap of $13.91 billion, a PE ratio of 17.65, a P/E/G ratio of 1.71 and a beta of 0.42.

Exelixis (NASDAQ:EXEL - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.85 by $0.06. Exelixis had a net margin of 35.33% and a return on equity of 42.17%. The company had revenue of $628.69 million for the quarter, compared to analysts' expectations of $636.40 million. During the same period in the previous year, the company posted $0.75 EPS. Exelixis's revenue was up 10.6% compared to the same quarter last year. Analysts anticipate that Exelixis, Inc. will post 3.19 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Exelixis news, Director Mary Beckerle sold 9,812 shares of Exelixis stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $53.66, for a total value of $526,511.92. Following the sale, the director owned 16,079 shares of the company's stock, valued at approximately $862,799.14. The trade was a 37.90% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.60% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on EXEL shares. Zacks Research raised shares of Exelixis from a "strong sell" rating to a "hold" rating in a research report on Tuesday, September 1st. Morgan Stanley raised their price target on Exelixis from $50.00 to $53.00 and gave the company an "equal weight" rating in a research note on Thursday, July 23rd. Royal Bank Of Canada lifted their price target on Exelixis from $43.00 to $46.00 and gave the stock a "sector perform" rating in a report on Tuesday, July 7th. William Blair reaffirmed an "outperform" rating on shares of Exelixis in a report on Friday. Finally, Weiss Ratings raised Exelixis from a "buy (b)" rating to a "buy (a-)" rating in a research report on Tuesday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Hold" and a consensus target price of $50.07.

Exelixis News Roundup

Here are the key news stories impacting Exelixis this week:

• Neutral Sentiment: The FDA extended its review of Exelixis’ application for zanzalintinib in combination with atezolizumab for patients with metastatic colorectal cancer by three months. The new decision target is March 2027. The extension does not indicate a rejection, but it delays regulatory clarity. U.S. FDA extends review of Exelixis' cancer drug
• Negative Sentiment: The delayed decision pushes back the potential launch and commercial ramp of zanzalintinib in colorectal cancer, reducing near-term visibility for investors and contributing to concern about Exelixis’ revenue outlook. Analysts are also assessing the effect of the announcement on stock volatility. Exelixis Stock Slips as FDA Delays Cancer Drug Review, Analyst Weighs In
• Neutral Sentiment: The FDA action follows Exelixis’ broader investor presentation and legal developments, but the reports provide no new change to the company’s existing earnings outlook or indication of a problem with its currently marketed products. Exelixis Presents at Citigroup's Biopharma Back to School Summit 2026

About Exelixis

Exelixis, Inc NASDAQ: EXEL is a biopharmaceutical company focused on discovering, developing and commercializing medicines for cancer and other serious diseases. The company's research and development activities center on targeted therapies designed to address biological pathways involved in tumor growth and progression.

Exelixis' principal product is cabozantinib, marketed in the United States as CABOMETYX tablets for certain patients with advanced renal cell carcinoma, hepatocellular carcinoma and radioactive iodine-refractory differentiated thyroid cancer.

Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.